Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full ...

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

Lantheus is enhancing its radiopharmaceutical ... the agreements to acquire Life Molecular and Evergreen Theragnostics. Both acquisitions are expected to close in the second half of 2025, subject ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...